1. Home
  2. TCRX vs CPHC Comparison

TCRX vs CPHC Comparison

Compare TCRX & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCRX
  • CPHC
  • Stock Information
  • Founded
  • TCRX 2018
  • CPHC 1994
  • Country
  • TCRX United States
  • CPHC United States
  • Employees
  • TCRX N/A
  • CPHC N/A
  • Industry
  • TCRX Biotechnology: Pharmaceutical Preparations
  • CPHC Services-Misc. Amusement & Recreation
  • Sector
  • TCRX Health Care
  • CPHC Consumer Discretionary
  • Exchange
  • TCRX Nasdaq
  • CPHC Nasdaq
  • Market Cap
  • TCRX 82.1M
  • CPHC 89.8M
  • IPO Year
  • TCRX 2021
  • CPHC 1994
  • Fundamental
  • Price
  • TCRX $1.93
  • CPHC $18.04
  • Analyst Decision
  • TCRX Strong Buy
  • CPHC
  • Analyst Count
  • TCRX 6
  • CPHC 0
  • Target Price
  • TCRX $9.50
  • CPHC N/A
  • AVG Volume (30 Days)
  • TCRX 572.1K
  • CPHC 6.3K
  • Earning Date
  • TCRX 08-11-2025
  • CPHC 08-07-2025
  • Dividend Yield
  • TCRX N/A
  • CPHC 1.52%
  • EPS Growth
  • TCRX N/A
  • CPHC N/A
  • EPS
  • TCRX N/A
  • CPHC 0.16
  • Revenue
  • TCRX $4,421,000.00
  • CPHC $60,605,931.00
  • Revenue This Year
  • TCRX $159.20
  • CPHC N/A
  • Revenue Next Year
  • TCRX N/A
  • CPHC N/A
  • P/E Ratio
  • TCRX N/A
  • CPHC $114.38
  • Revenue Growth
  • TCRX N/A
  • CPHC N/A
  • 52 Week Low
  • TCRX $1.02
  • CPHC $16.75
  • 52 Week High
  • TCRX $7.44
  • CPHC $22.93
  • Technical
  • Relative Strength Index (RSI)
  • TCRX 63.03
  • CPHC 43.79
  • Support Level
  • TCRX $1.75
  • CPHC $18.25
  • Resistance Level
  • TCRX $1.96
  • CPHC $18.99
  • Average True Range (ATR)
  • TCRX 0.14
  • CPHC 0.21
  • MACD
  • TCRX 0.01
  • CPHC -0.08
  • Stochastic Oscillator
  • TCRX 94.00
  • CPHC 10.30

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About CPHC Canterbury Park Holding Corporation 'New'

Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.

Share on Social Networks: